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Impact of Delay to Angioplasty
in Patients With Acute Coronary Syndromes
Undergoing Invasive Management
Analysis From the ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) Trial
Paul Sorajja, MD,* Bernard J. Gersh, MB, CHB, DPHIL,* David A. Cox, MD,‡
Michael G. McLaughlin, MD,† Peter Zimetbaum, MD,† Costantino Costantini, MD,#**
Thomas Stuckey, MD,§ James E. Tcheng, MD,储 Roxana Mehran, MD,#** Alexandra J. Lansky, MD,#**
Cindy L. Grines, MD,¶ Gregg W. Stone, MD#**
Rochester, Minnesota; Boston, Massachusetts; Charlotte, Greensboro, and Durham, North Carolina;
Royal Oak, Michigan; and New York, New York
Objectives

The aim of this study was to determine the impact of delay to angioplasty in patients with acute coronary
syndromes (ACS).

Background

There is a paucity of data on the impact of delays to percutaneous coronary intervention (PCI) in patients with
non–ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing an invasive management strategy.

Methods

Patients undergoing PCI in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial were
stratified according to timing of PCI after clinical presentation for outcome analysis.

Results

Percutaneous coronary intervention was performed in 7,749 patients (median age 63 years; 73% male) with
NSTE-ACS at a median of 19.5 h after presentation (⬍8 h [n ⫽ 2,197], 8 to 24 h [n ⫽ 2,740], and ⬎24 h [n ⫽
2,812]). Delay to PCI ⬎24 h after clinical presentation was significantly associated with increased 30-day mortality,
myocardial infarction (MI), and composite ischemia (death, MI, and unplanned revascularization). By multivariable
analysis, delay to PCI of ⬎24 h was a significant independent predictor of 30-day and 1-year mortality. The incremental risk of death attributable to PCI delay ⬎24 h was greatest in those patients presenting with high-risk features.

Conclusions

In this large-scale study, delaying revascularization with PCI ⬎24 h in patients with NSTE-ACS was an independent predictor of early and late mortality and adverse ischemic outcomes. These findings suggest that urgent
angiography and triage to revascularization should be a priority in NSTE-ACS patients. (J Am Coll Cardiol 2010;
55:1416–24) © 2010 by the American College of Cardiology Foundation

There is a general consensus that an early invasive strategy
leads to improved clinical outcomes in moderate- and
high-risk patients with non–ST-segment elevation acute
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coronary syndromes (NSTE-ACS) (1–5). Randomized
clinical trials have demonstrated that the benefits of an early
invasive strategy in these patients occur early, persist in
long-term follow-up, and are particularly evident in highrisk patients. These observations have led to the adoption of
an early invasive strategy in the management of many
patients with NSTE-ACS, with angiography typically performed within 48 to 72 h of hospital admission (6,7).
See page 1425

Nonetheless, within the framework of an early invasive
strategy, there is a paucity of data on precisely when
angiography and revascularization should take place in
patients with NSTE-ACS (8 –12). Expeditious angiogra-
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phy and revascularization might hasten definitive management, reduce the need for prolonged antithrombotic therapy
and its potential associated complications (i.e., bleeding),
and lead to shortened hospital stay. One modest-sized
randomized trial of immediate versus delayed cardiac catheterization in patients with NSTE-ACS found a significant
reduction in death and myocardial infarction (MI) among
patients who underwent angiography ⬍6 h after hospital
admission versus several days later (13). A second, larger
randomized trial found no benefit of early intervention for
NSTE-ACS, except in those patients who were at high risk
(14). Some studies have reported fewer complications
when revascularization with percutaneous coronary intervention (PCI) is performed after several days of medical
stabilization (11). Because the implications for patient
management and the timing of triage are potentially
substantial, further data are needed on the relationship
between clinical presentation and time to revascularization in patients with NSTE-ACS.
Accordingly, with data from the large-scale, prospective, controlled ACUITY (Acute Catheterization and
Urgent Intervention Triage strategY) trial, we sought to
examine the appropriate timing of revascularization with
PCI after clinical presentation in patients with NSTE-ACS.
Methods
Study population. The details of the ACUITY trial protocol have been previously published (15,16). Briefly, the
ACUITY trial was a prospective, open-label, randomized,
multicenter trial in which patients with NSTE-ACS undergoing an early invasive management strategy were randomized
to receive 1 of 3 antithrombotic regimens: 1) unfractionated or
low molecular weight heparin plus a glycoprotein IIb/IIIa
inhibitor; 2) bivalirudin plus a glycoprotein IIb/IIIa inhibitor;
or 3) bivalirudin alone. Patients were eligible for study
participation if they were ⱖ18 years of age with symptoms
of NSTE-ACS within the preceding 24 h and if 1 or more
of the following criteria were met: new ST-segment depression or transient elevation of ⱖ1 mm; elevations in the
troponin I, troponin T, or creatine kinase-MB levels;
known coronary artery disease; or all 4 other variables for
predicting Thrombolysis In Myocardial Infarction (TIMI)
risk scores for unstable angina (17). Exclusion criteria were
ST-segment elevation MI or cardiogenic shock; bleeding
diathesis or major bleeding episode within 2 weeks; thrombocytopenia; a calculated creatinine clearance rate of ⬍30
ml/min; recent administration of abciximab, warfarin,
fondaparinux, fibrinolytic agents, bivalirudin, or 2 or more
doses of low-molecular-weight heparin; and allergy to any
of the study drugs or to iodinated contrast medium that
could not be controlled in advance with medication.
Patients who were randomized to a glycoprotein IIb/IIIa
receptor inhibitor were randomized further to receive the
drug immediately after randomization (i.e., upstream) or
only at the time of PCI. Angiography was performed within
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72 h in all patients. Of the 13,819
Abbreviations
and Acronyms
patients enrolled in the ACUITY
trial, 7,789 patients (56%) underCABG ⴝ coronary artery
went PCI at the discretion of the
bypass grafting
local physician after diagnostic anMI ⴝ myocardial infarction
giography. The timing of angiogNSTE-ACS ⴝ non–STraphy was known in 7,749 of these
segment elevation acute
patients who comprise the study
coronary syndrome
cohort examined in the present
PCI ⴝ percutaneous
coronary intervention
investigation.
Definitions and end points.
TIMI ⴝ Thrombolysis In
Myocardial Infarction
Clinical follow-up was performed
at 1 month and 12 months. As
previously described, 3 primary
end points at 30 days were prespecified: composite ischemia
(death from any cause, MI, or unplanned revascularization
for ischemia), major bleeding (not related to coronary artery
bypass grafting [CABG]), and net adverse clinical events
(composite ischemia or major bleeding) (15,16). Major
bleeding was defined as intracranial or intraocular bleeding, hemorrhage at the access site requiring intervention,
hematoma with a diameter of ⬎5 cm, a reduction in
hemoglobin levels of ⱖ4 g/dl without an overt bleeding
source or ⱖ3 g with such a source, reoperation for
bleeding, or transfusion of a blood product (15,16). A
clinical events committee that was blinded to treatment
assignment adjudicated all study end points (15,16).
Data analysis. Patients were stratified by time from hospital presentation to revascularization with PCI into 3
approximately equal-size groups: ⬍8 h, 8 to 24 h, and ⱖ24
h. To analyze the acute risk of the patient as a potential
confounder, the TIMI risk score for NSTE-ACS was
calculated for each patient (0 to 2 ⫽ low-risk; 3 to 4 ⫽
intermediate-risk; 5 to 7 ⫽ high-risk) (17). Cox proportional hazards models were constructed to determine the
independent correlates of adverse event outcomes with the
following nominal candidate variables: age ⱖ75 years, male
sex, diabetes mellitus, current smoker, hypertension, abnormal cardiac biomarkers, ST-segment deviation ⱖ1 mm,
prior transient ischemic attack or stroke, anemia (baseline
hemoglobin ⬍12 g/dl or hematocrit ⬍36% for women and
hemoglobin ⬍13 g/dl or hematocrit ⬍39% for men),
creatinine clearance ⬍60 ml/min, multivessel coronary disease, recent medication use before admission (aspirin, betablockers, statins, prior antithrombin use, angiotensinconverting enzyme inhibitors or angiotensin receptor
blockers, thienopyridines), and time duration ⱖ24 h from
hospital admission to PCI. Event rates were determined and
displayed with the Kaplan-Meier method with comparisons
performed with the log-rank test. Categorical variables were
compared with the Fisher exact test for pairwise comparisons and the chi-square test for trend for multiple comparisons. Continuous variables are expressed as medians with
interquartile ranges in parentheses and were compared with
the nonparametric Kruskal-Wallis test.
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Results
Baseline characteristics. Tables 1 and 2 list the baseline,
clinical, and angiographic characteristics of the overall study
cohort, stratified according to time from hospital presentation to revascularization with PCI. Median time to PCI was
19.5 h in all patients and 3.5 h, 18.1 h, and 39.2 h in those
undergoing PCI in ⬍8 h, 8 to 24 h, and ⬎24 h, respectively,
after hospital presentation. Patients who underwent PCI
⬎24 h after hospital presentation more frequently had
elevation of cardiac troponins, high TIMI risk score (5 to 7),
left main culprit lesion, baseline TIMI flow grade 3, prior
history of diabetes mellitus, MI, left main disease, CABG,
and prior use of antithrombins and thienopyridines. Patients with delay to PCI also had a lower incidence of home
aspirin and beta-blocker use compared with patients who
underwent earlier PCI. There was no difference in procedural success and final TIMI flow after PCI for the 3 patient
groups.
30-day and 1-year clinical outcomes. Clinical follow-up
was available in 7,627 patients (98%) at 30 days. There were
no significant differences in the 30-day or 1-year rates of
death or the combined end point of death or MI in patients
who underwent PCI ⬍8 h versus those who had PCI ⬎8 to

24 h after clinical presentation. In contrast, patients who
underwent PCI ⬎24 h after clinical presentation had higher
rates of death, MI, composite ischemia, and net adverse
clinical events at 30 days in comparison with those who
underwent earlier PCI (Fig. 1, Table 3). The increase in
mortality and combined death or MI among patients who
underwent PCI ⬎24 h after clinical presentation persisted
at 1-year follow-up (Fig. 2).
The rate of non-CABG–related major bleeding was
lowest among patients who underwent PCI between 8 and
24 h after clinical presentation, with no significant difference present between patients who underwent PCI ⬍8 h
and those who underwent PCI ⬎24 h after hospital admission. There also was no relation between PCI timing and
final TIMI flow grade achieved with PCI. However, patients who underwent PCI ⬎24 h after clinical presentation
had the lowest incidence of early and late unplanned
revascularization (Table 3). This lower incidence was
present even though both the prevalence of multivessel
disease and number of vessels treated with PCI were similar
across the 3 PCI timing groups.
Impact of randomization. Within each of the 3 PCI
timing groups, there were no significant differences in

Baseline
According toAccording
Time to PCI
Table 1 Characteristics
Baseline Characteristics
to Time to PCI
Time to PCI

Age, yrs, median (range)

<8 h

8–24 h

>24 h

p Value
(3 Groups)
⬍0.0001

63 (25–92)

62 (21–92)

63 (30–95)

Male sex (%)

73.6

72.8

73.0

0.83

U.S. patients (%)

51.4

64.1

48.2

⬍0.0001

84 (75–95)

85 (75–97)

83 (73–95)

0.001

26.1

27.2

29.2

0.04

8.6

7.6

8.6

0.30

Current smoker

30.2

32.3

30.1

0.14

Hyperlipidemia

55.4

56.8

55.8

0.59
0.45

Weight, kg, median (IQR)
Medical history (%)
Diabetes mellitus
Insulin-requiring

Hypertension

66.5

64.8

65.3

Prior myocardial infarction

27.6

31.1

31.8

0.004

Creatinine clearance ⬍60 ml/min

17.5

17.3

20.2

0.01

Prior CABG surgery

14.4

18.0

19.3

⬍0.0001
⬍0.0001

Medical therapy at presentation (%)
Aspirin

73.0

68.6

67.0

Beta-blockers

52.6

48.5

47.3

0.0005

Statins

46.4

47.6

47.4

0.64
⬍0.0001

Prior antithrombin use

58.2

69.3

67.5

ACE inhibitors/ARBs

42.3

39.3

41.7

0.07

Thienopyridines

64.5

64.9

68.1

⬍0.0001

Elevation of cardiac biomarkers (%)

64.1

64.6

66.2

0.29

Elevation of troponin (%)

62.5

64.2

66.3

0.03

ST-segment deviation ⱖ1 mm (%)

39.3

32.1

36.6

⬍0.0001

0–2

15.7

15.6

16.7

0.51

3–4

54.0

55.4

50.9

0.006

5–7

30.2

29.1

32.4

0.04

TIMI risk score

ACE ⫽ angiotensin-converting enzyme; ARB ⫽ angiotensin-receptor blocker; CABG ⫽ coronary artery bypass grafting; IQR ⫽ interquartile range; PCI ⫽
percutaneous coronary intervention; TIMI ⫽ Thrombolysis In Myocardial Infarction.
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Procedural Results
Angiographic
Characteristics
According
and
to Time to PCI
Angiographic
Characteristics
and
Table 2
Procedural Results According to Time to PCI

Event Rates30-Day
Unadjusted
According
and to
1-Year
Time to
Unadjusted
30-Day
andPCI
1-Year
Table 3
Event Rates According to Time to PCI

Time to PCI

Time to PCI

<8 h

8–24 h

>24 h

p Value
(3 Groups)

<8 h

8–24 h

>24 h

p Value
(3 Groups)

Left anterior descending

44.8

41.4

43.1

0.06

Left circumflex

34.6

33.7

36.2

0.14

Death

0.8

0.5

1.7

⬍0.0001

Myocardial infarction

4.9

5.6

8.0

Right coronary artery

34.4

39.7

35.8

⬍0.0001

0.0003

Death or myocardial infarction

5.6

6.0

9.0

1.0

1.6

2.0

⬍0.0001

0.01

Unplanned revascularization

4.2

3.4

2.8

0.02

Composite ischemia

7.9

7.9

10.4

0.001

Culprit lesion (%)

30-day (%)

Left main
Baseline TIMI flow grade (%)
0/1

30.3

22.2

21.5

⬍0.0001

Non-CABG major bleeding

2

21.9

19.2

16.5

⬍0.0001

Net clinical outcome

3

51.5

63.0

66.8

⬍0.0001

Unfractionated heparin

19.4

17.4

12.3

⬍0.0001

Low-molecular weight heparin

13.1

16.0

20.3

⬍0.0001

Bivalirudin

67.5

66.6

67.4

0.78

Antithrombin treatment

Glycoprotein IIb/IIIa receptor
inhibitor usage (%)
Upstream

35.0

34.0

31.7

0.03

At time of PCI

31.1

33.1

33.9

0.11

Stent implanted (%)

91.8

92.2

91.8

0.82

Drug-eluting stent

54.7

65.0

58.2

⬍0.0001

0/1

2.8

2.4

2.7

0.67

2

2.9

2.2

2.5

0.37

3

95.3

96.5

96.0

0.10

Final TIMI flow grade (%)

PCI ⫽ percutaneous coronary intervention; TIMI ⫽ Thrombolysis In Myocardial Infarction.

30-day mortality, MI, unplanned revascularization, or composite ischemia among the 3 randomized antithrombotic
regimens (p ⬎ 0.05 for all comparisons). The rate of
non-CABG major bleeding, however, was lower among
patients assigned to bivalirudin alone compared with a
glycoprotein IIb/IIIa inhibitor-based regimen, regardless of
the time delay to PCI (Fig. 3).
12
10

P=0.003

PCI <8 hrs
PCI 8 to 24 hrs

30-day Incidence (%)

8.8

P=0.99

8.1

8.2

8
P=0.48

6.3
5.6

P=0.008

p=0.02
P<0.0001

2

1.7
P=0.24

0.8

0.6

0
Death

Figure 1

4.8

6.8

0.005

11.6

15.5

⬍0.0001

Death

2.9

2.2

4.3

⬍0.0001

Myocardial infarction

7.8

7.7

10.7

⬍0.0001

Death or myocardial infarction

10.1

9.3

13.7

⬍0.0001

Unplanned revascularization

14.6

11.2

10.5

⬍0.0001

Composite ischemia

19.5

16.8

20.3

0.002

1-year (%)

CABG ⫽ coronary artery bypass grafting; PCI ⫽ percutaneous coronary intervention.

TIMI risk score, PCI timing, and outcome. Delay to PCI
⬎24 h after clinical presentation was associated with significant
increases in the rates of 30-day death and death or MI among
both intermediate and high-risk patients (Fig. 4). In comparison with patients who had earlier PCI, high-risk patients
(TIMI score ⫽ 5 to 7) who had PCI delay ⬎24 h also
demonstrated an approximately 2-fold increase in 30-day
mortality. The relation between PCI delay ⬎24 h and risk
of death at 1-year follow-up persisted irrespective of the
baseline TIMI risk score, although the greatest difference in
death was evident in the higher-risk patients (Fig. 5).
After multivariable adjustment for differences in baseline
characteristics, a delay to PCI ⬎24 h after clinical presentation was a strong independent predictor of both death and
the combined end point of death or MI at 30 days and 1
year (Tables 4 and 5).
Discussion

10.1

P<0.0001

6

6.2
12.7

P=0.001
P<0.0001

PCI >24 hrs

4

1419

Death/MI

Composite Ischemia

Timing of PCI After Clinical Presentation
and 30-Day Outcomes

The end point of composite ischemia consists of death from any cause,
myocardial infarction (MI), or unplanned revascularization for ischemia. PCI ⫽
percutaneous coronary intervention.

The principal findings of this investigation are: 1) delay to
PCI ⬎24 h after clinical presentation in patients with
NSTE-ACS is a strong, independent predictor of increased
30-day and 1-year mortality and combined death or MI;
2) the hazard of PCI delay is greatest in the highest-risk
patients and is independent of antithrombin randomization;
and 3) the benefits of bivalirudin monotherapy in reducing
hemorrhagic complications while affording similar suppression of ischemic complications compared with a glycoprotein IIb/IIIa inhibitor based-regimen is independent of
time from presentation to PCI.
Although clinical trials have established the benefits of an
early invasive strategy for the majority of patients presenting
with NSTE-ACS, the appropriate timing of angiography
and revascularization has not been resolved. In prior ACS
studies, the timing of angiography among patients managed
with an invasive strategy has varied considerably, ranging
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A
5

PCI <8hrs
PCI 8 to 24 hrs
PCI >24 hrs

Death (%)

4

3

2
p<0.0001
1

0
0

30

60

90

120

150

180

210

240

270

300

330

360

Follow-up (days)

B
25

PCI <8hrs
PCI 8 to 24 hrs
PCI >24 hrs

in Acute Coronary Syndromes) trial, early angiography
(median time, 14 h) did not lead to better outcomes except
in patients who were at high risk (14). Other observational
studies describing the impact of the timing of angiography
and revascularization on the outcomes of patients with ACS
have been inconsistent, with clinical benefit from expeditious angiography being evident in some but not all studies
(8 –12).
In the present large-scale, multicenter, randomized trial,
there was a strong, independent association of PCI delay
⬎24 h after clinical presentation with NSTE-ACS and
subsequent mortality and adverse clinical outcomes. An
increase in mortality was observed early with PCI delay and
persisted throughout the 1-year follow-up period and was
particularly evident among high-risk patients. There also
was an increased risk of MI and composite ischemia among
patients with PCI delay ⬎24 h. Of note, the 30-day rate of
death or MI for patients undergoing PCI ⬍8 h after
hospital admission in the present investigation (5.6%) was
similar to that observed among patients who underwent
early angiography in the ISAR-COOL trial (5.9%) (13).
The present findings also are consistent with those recently

15

10
9

10
p<0.0001
5

0
0

30

60

90

120

150

180

210

240

270

300

330

360

Non-CABG major bleeding (%)

Death/MI (%)

20

Follow-up (days)

8

Heparin + Gpi
Bivalirudin + Gpi
Bivalirudin alone

9.9

7.8

7.6

7.3

7
6

5.5
4.9

5

4.0

*

4

*

3.5

3.3

3
2
1
0

Figure 2

Occurrence of Death at
1-Year Follow-Up According to
Timing of PCI After Clinical Presentation

<8 hrs

12

from 1 to 4 days after clinical presentation (1–5). One small
randomized study has been published in which the optimal
timing of PCI in patients with NSTE-ACS has been
examined, the ISAR-COOL (Intracoronary Stenting With
Antithrombotic Regimen Cooling-Off) trial. In this study
there was a significantly lower risk of death or MI in
patients with NSTE-ACS who underwent angiography ⬍6
h after clinical presentation (median time, 2.4 h) in comparison with those randomized to angiography after 3 to 5
days of antithrombotic therapy (5.9% vs. 11.6%, p ⫽ 0.04)
(13). In a second, larger randomized trial of 3,031 patients
with NSTE-ACS, the TIMACS (Timing of Intervention

>24 hrs

Heparin + Gpi
Bivalirudin + Gpi
Bivalirudin alone

11.2
10.0

30-day composite ischemia (%)

Increasing delay in percutaneous coronary intervention (PCI) after clinical presentation was significantly associated with greater mortality (A) and combined
death or myocardial infarction (MI) (B) at 1-year follow-up (p ⬍ 0.0001,
log-rank).

8 to 24 hrs

10.0

10
8.6
8.2

8

8.4

7.7

7.4

7.1

6

4

2

0
<8 hrs

Figure 3

8 to 24 hrs

>24 hrs

30-Day Incidence of Major
Bleeding and Composite Ischemia

*p ⬍ 0.05 versus both heparin ⫹ Gpi and bivalirudin ⫹ Gpi. CABG ⫽ coronary
artery bypass grafting; Gpi ⫽ glycoprotein inhibitor.
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4

PCI <8 hrs
PCI 8 to 24 hrs
PCI >24 hrs

2.9

30-day death (%)

2

*

1.2

1.4

1.3

1.1
0.8

30-day composite ischemia (%)

**

3

1

PCI <8 hrs
PCI 8 to 24 hrs
PCI >24 hrs

14
12

13

10.8

†

9.9

9.5

10
8

8

7.2
6.6
5.9

6

5.6

4
2

0. 3

0. 3

Low

Intermediate

0

0

0
Low

High

Intermediate

10

8.9

7.6

6.2
5.4

5.5

4.5

4

18

8.3

6.9

6

20

**

**

3.6

2
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30-Day Outcomes by Patient Risk and Timing of PCI

Risk for each patient was classified according to Thrombolysis In Myocardial Infarction (TIMI) risk score (0 to 2 ⫽ low, 3 to 4 ⫽ intermediate, 5 to 7 ⫽ high). *p ⬍ 0.05
versus PCI ⫽ 8 to 24 h; **p ⬍ 0.05 versus both PCI ⫽ 8 to 24 h and PCI ⬍8 h; †p ⬍ 0.05 versus PCI ⬍8 h. PCI ⫽ percutaneous coronary intervention.

reported in a post hoc analysis from the SYNERGY
(Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa inhibitors) trial,
which reported less death and MI for patients undergoing
angiography within 6 h after clinical presentation (12).
In the ACUITY trial, timing of angiography and PCI
was left to the discretion of the local investigator. Prior
studies have identified clinical variables predictive of angiographic delay in NSTE-ACS patients (12). To help address
potential selection bias, we examined the hazard of PCI
delay according to patient risk at presentation (i.e., TIMI
score) and also after multivariable adjustment for differences
in baseline characteristics. In these analyses, there was an
association between increased patient risk and the hazard of
PCI delay. These findings are consistent with those of the
TIMACS trial, which demonstrated less death, MI, and
stroke for high-risk patients with NSTE-ACS who were
randomized to earlier angiography (14). Nonetheless, even
among the low-risk patients (TIMI score ⫽ 0 to 2), there
was a significantly higher 1-year mortality rate in our study
among those who had PCI ⬎24 h after clinical presentation
than among patients who had earlier PCI. Furthermore,
multivariable analyses confirmed the independent impact of

PCI delay ⬎24 h in the overall study population for both
early and late adverse events.
The present investigation, the largest to date examining
the impact of treatment-related delays on patient outcomes,
in which antithrombotic therapy was systematically administered to all patients before an early invasive management
strategy, reconciles and extends the conflicting findings
from previous reports examining the implications of treatment delays in ACS patients. In the PURSUIT (Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trial, the lowest rates of
death and MI occurred among those treated with eptifibatide and PCI within 24 h of clinical presentation (18). In
this study, however, no difference in death or MI according
to timing of PCI was noted for patients treated without a
glycoprotein IIb/IIIa receptor inhibitor (18). Benefits of
expeditious angiography for patients with NSTE-ACS
have been observed in other studies in which antithrombotic and antiplatelet therapy was administered early as
per current guideline recommendations (6,8,12) but not
in others in which these therapies were used less frequently (10,11). Intense antiplatelet and antithrombotic
therapy might be specifically beneficial in patients with
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8
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95% CI

p Value

Age ⱖ75 yrs

4.18

2.59–6.73

⬍0.0001

Male sex

1.39

0.82–2.35

0.22

Anemia

1.94

1.18–3.19

0.009

Prior stroke or TIA

1.71

1.07–2.73

0.02

Elevation of cardiac biomarkers

4.25

2.14–8.42

⬍0.0001

ST-segment deviation ⱖ1 mm

1.72

1.08–2.73

0.02

Known CAD

1.70

1.04–2.77

0.04

PCI delay ⬎24 h

2.14

1.35–3.39

0.001

Age ⱖ75 yrs

2.66

1.94–3.65

⬍0.0001

Male sex

1.26

0.93–1.70

0.13

Anemia

1.54

1.14–2.07

0.005

Creatinine clearance ⬍60 ml/min

1.63

1.18–2.25

0.003

Prior stroke or TIA

1.43

1.06–1.91

0.02

Elevation of cardiac biomarkers

2.07

1.51–2.84

⬍0.0001

1-yr death

0

B

Hazard Ratio
30-day death

P=0.02

6

ST-segment deviation ⱖ1 mm

1.51

1.15–1.97

0.003

Known CAD

1.90

1.41–2.56

⬍0.0001

Diabetes mellitus

1.82

1.41–2.34

⬍0.0001

PCI delay ⬎24 h

1.57

1.20–2.04

0.0008

CAD ⫽ coronary artery disease; CI ⫽ confidence interval; PCI ⫽ percutaneous coronary intervention; TIA ⫽ transient ischemic attack.

repeat revascularization (22). Nevertheless, in the present
study, rates of death and MI were lowest among patients
who had early PCI, without increased bleeding, although
the rates of unplanned revascularization were higher in this
group. The explanation underlying the increased incidence
of both early and late unplanned repeat revascularization
among the early PCI group, also noted from the PURSUIT
trial (8), is not known but might be due to more extensive
and/or severe vascular disease in patients requiring earlier

4
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Figure 5

1-Year Mortality by Patient Risk and Timing of PCI

Risk for each patient was classified according to Thrombolysis In Myocardial
Infarction (TIMI) score (0 to 2 ⫽ low, 3 to 4 ⫽ intermediate, 5 to 7 ⫽ high).
(A) Low-risk; (B) intermediate-risk; (C) high-risk. PCI ⫽ percutaneous coronary
intervention.

NSTE-ACS undergoing very early PCI, in whom platelet activation is heightened, facilitating the safe performance of early PCI (19).
Prolonged medical therapy might theoretically be beneficial in decreasing the angiographic thrombus burden in
patients with NSTE-ACS (20,21). In a pooled analysis of
angiographic trials, the presence of thrombus was associated
with a higher rate of abrupt closure, MI, and in-hospital

95% CI

p Value

30-day death or myocardial infarction
Age ⱖ75 yrs

1.18

0.93–1.50

0.18

Creatinine clearance ⬍60 ml/min

1.36

1.08–1.71

0.01

Elevation of cardiac biomarkers

1.40

1.14–1.71

0.001

ST-segment deviation ⱖ1 mm

1.22

1.02–1.46

0.03

Known CAD

1.47

1.21–1.79

0.0001

PCI delay ⬎24 h

1.51

1.27–1.80

⬍0.0001

1-yr death or myocardial infarction
Age ⱖ75 yrs

1.14

0.95–1.38

0.16

Anemia

1.20

1.01–1.43

0.04
⬍0.0001

Creatinine clearance ⬍60 ml/min

1.53

1.27–1.83

Prior stroke or TIA

1.28

1.06–1.53

0.009

Elevation of cardiac biomarkers

1.42

1.21–1.66

⬍0.0001

ST-segment deviation ⱖ1 mm

1.17

1.01–1.35

0.04

Known CAD

1.79

1.51–2.12

⬍0.0001

Diabetes mellitus

1.18

1.01–1.37

0.03

PCI delay ⬎24 h

1.36

1.18–1.56

⬍0.0001

Abbreviations as in Table 4.
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intervention or greater systemic inflammation in patients with
NSTE-ACS requiring early PCI (8,23,24). Nonetheless, these
data in aggregate support expeditious angiography and revascularization when appropriate in moderate- and high-risk
patients with NSTE-ACS after initial treatment with antiplatelet and antithrombotic therapy.
Several inherent limitations of the present analysis should
be acknowledged, including selection and survivor biases.
Precise reasons for PCI delay were not prospectively collected, and there were significant baseline differences between groups. Although multivariable adjustment was used
to correct for measured differences between the groups, we
cannot exclude the presence of unmeasured confounders.
For example, it cannot be known with certainty whether
patients who underwent late PCI did so because they were
too ill for earlier angiography or were more stable, thus not
requiring very early angiography. It is important to note that
this study is a post hoc analysis, and our findings should
therefore be interpreted as hypothesis-generating. Of note,
in analyses that examined outcome according weekend or
weekday presentation, there were no differences in mortality, ischemic events, or bleeding. Bleeding rates were lower
in the bivalirudin monotherapy arms for each of the PCI
timing groups. Mortality did not differ according to the
randomized antithrombotic regimen within each PCI timing group, but the 30-day death rates were low (ⱕ1%).
Despite these caveats, the present findings—taken in concert with those from earlier observational studies, the randomized ISAR-COOL trial, and the randomized TIMACS
trial—suggest that patients with moderate- and high-risk
NSTE-ACS in whom an early invasive strategy is planned
benefit from urgent triage (within 8 h) to angiography and
revascularization when appropriate, particularly for those
patients in whom high-risk features are present. Adopting a
policy of expedited angiography for all patients with NSTEACS would require additional hospital staffing and potentially greater resource use and costs due to the large number
of NSTE-ACS patients admitted to hospitals each year
(⬎1.5 million in the U.S.) (25). However, this economic
burden might be counterbalanced by significant reductions
in mortality, ischemic outcomes, and shorter hospital stays.
The present study thus warrants further large-scale, randomized investigations of expedited versus delayed angiography in patients with NSTE-ACS in whom an invasive
management strategy is planned, with co-primary end
points of clinical efficacy and cost-effectiveness.
Reprint requests and correspondence: Dr. Gregg W. Stone, The
Cardiovascular Research Foundation, 111 East 59th Street, 11th
Floor, New York, New York 10022. E-mail: gstone@crf.org.
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